secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2024-09-13T23:59:59+00:00
Accession:  0000950170-24-106464
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health enters ATM equity facility up to $10M; appoints Lisa Wolf as interim CFO
--------------------------------------------------------------------------------

- Equity Distribution Agreement with Maxim Group for at-the-market sales of common stock up to $10M aggregate offering price; current baby shelf limit $1.44M.
- Maxim receives 3.0% commission; Tivic reimburses up to $40K expenses plus $5K per bringdown.
- Kimberly Bambach resigns as interim CFO effective Oct 1, 2024; remains advisor for strategic transactions.
- Lisa Wolf appointed interim CFO effective Oct 1, 2024; paid $275/hour as non-employee consultant; has served Tivic since June 2022 via Murdock Martell.
- Wolf brings 30 years experience, including CAO at Resonant (RESN) and CPA at Arthur Andersen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017024106464/0000950170-24-106464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017024106464/tivc-20240912.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-106464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer